



IMPACT REPORT 2025





RADIOMOLECULAR PRECISION ONCOLOGY

FOR PATIENTS WORLDWIDE

THE ICPO FOUNDATION.

Table of Contents

4 Highlights 2025

6 Vision & Mission

8 Facts & Figures

10 ICPO Centers' Network

16 ICPO Academy for Theranostics

22 ICPO Research Support

26 Scientific Advisory Board

28 ICPO Community & Events

34 Patient Advocacy

36 Key Goals for 2026

38 Donate & Support

40 ICPO Organization

42 Thank You Letter

44 Sponsors ICPO Forum 2025

HIGHLIGHTS 2025

2025 was a breakthrough year for the ICPO Foundation, emerging as a truly global non-profit player in Theranostics

The ICPO Foundation has been driving meaningful progress for cancer patients globally, with focus on improved patient access to Theranostics and better clinical outcomes. With the aspiration of reaching 1 million patients treated worldwide with high standards of care, ICPO has developed a unique strategy that takes into account regional and national realities and the different maturity levels of Theranostics centers. This has been complemented through strong partnerships with leading medical societies and scientific experts, non-profits, patient associations, governmental institutions and industry players.

The ICPO Center accreditation scheme became the cornerstone of a global network of ICPO Theranostics Clinical Centers of Excellence. The ICPO Center network grew from 11 centers in 2024 to over 50 in 2025 – shaping a global ICPO Community in Theranostics that spans across eight world regions. Looking ahead, we aim to double this number in 2026.

Enabling healthcare professionals to gain democratic access to world-class, certified continued education in Theranostics is rooted in the mission of the ICPO Foundation. In 2025, the ICPO Academy for Theranostics reached 800 alumni from more than 30 countries and incorporated new languages such as German, Korean, and Japanese. Accredited by the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), the ICPO Academy for Theranostics has been endorsed by 11 international nuclear medicine societies and features the International Atomic Energy Agency (IAEA) as a cooperation partner. The next level of the Academy, which is under development, will comprise clinical cases and multidisciplinary tumor boards by illustrating real-world medical scenarios from various regions in the world.



“Our energy is global, our purpose tangible – making Theranostics accessible to every patient in need.”

Sen. h.c. Udo J. Vetter
Chairman of the Board of Trustees

Since 2019, ICPO has supported groundbreaking Theranostics research thanks to 1,6 million Euros in grants, including 225,000 Euros in 2025 alone. A pioneering call for applications to accelerate the use of AI in Theranostics was launched by ICPO at the end of 2025. The successful grant recipient will conduct research on how to structure, annotate and standardize imaging and therapy datasets.

More than 400 healthcare professionals joined the ICPO Theranostics Virtual Summit 2024, followed by over 240 attendees at the ICPO Forum for Theranostics 2025 in Munich last May. Stay tuned for the 2026 and 2027 editions, which promise world-class programs and forward-thinking discussions.

Partnerships are crucial to maximize the impact of ICPO’s mission. In line with this, ICPO joined the RLT Angels Association as a co-founder alongside EANM and industry partners GE Healthcare, Novartis, and RayzeBio, a BMS company. The RLT Angels Association is a public-private partnership, where members advocate collectively for better patient outcomes and aim for large-scale targets such as 1 million patients treated in 1000 centers. All ICPO initiatives contribute to this collective effort and, in return, benefit from it.

Thanks to the passion of many scientific leaders, as well as the generous contributions from partners and donors, we are building a future where all patients in need can be treated with Theranostics – an innovative and personalized approach to cancer care.

Join us and support our mission!

Yours sincerely,

Sen. h.c. Udo J. Vetter
Chairman of the Board of Trustees

Odile Jaume
CEO



“Seeing the ICPO Foundation grow from vision to reality and impacting patients’ lives fills me with pride and emotion.”

Odile Jaume
CEO

VISION & MISSION

The ICPO Foundation supports a new era of cancer care ...

Cancer is one of the most significant health challenges of our time, and patients worldwide need more effective treatments. Recognizing a paradigm shift in cancer care to a personalized approach, the ICPO Foundation aims to scale patient access to Radiomolecular Precision Oncology - also known as Theranostics – to improve patient outcomes worldwide.

Pivotal trials have demonstrated that certain radiopharmaceuticals have a favorable benefit-risk profile in advanced neuroendocrine tumors and metastatic prostate cancer.¹ In major EU countries and the UK only, required treatment slots are projected to rise from about 150,000 in 2025 to 500,000 in 2033 – nearly a five-fold increase.² With EMA and FDA approvals expanding patient access to Theranostics, the path is now open for advancing and registering radiopharmaceutical treatments for more cancer indications.³

In collaboration with experts and global partners, the ICPO Foundation is on a mission to establish an international network of accredited ICPO Theranostics Centers of Excellence with the aim to treat in the future 1 million patients worldwide regardless of their geography.

Dedicated to education and scientific progress in Theranostics, ICPO aims to grow the talent pool of clinicians and to support the development of young researchers, while cultivating a strong, collaborative ICPO Community. This fosters the fruitful exchange of clinical experience and the adoption of international best practices.

The unique regional and local strategy of ICPO allows to effectively grow the number of patients treated in Theranostics centers, while improving their quality of care and clinical outcomes. This, in turn, leads to the adoption of new technologies in the field of radiopharmaceuticals development, medical equipment and AI-enriched software suites.

All of ICPO's efforts are made possible through close collaboration with leading associations and medical societies, public and governmental organizations, as well as industry players. By joining forces we are creating global impact in Theranostics.



...
by scaling global patient access to Theranostics
...

...
through a network of Theranostics Centers of Excellence and
...

...
strong partnerships enabling innovation adoption.

ICPO THERANOSTICS CENTERS
Supporting centers in raising clinical standards to next-level international accreditation.

ICPO ACADEMY FOR THERANOSTICS
Grow the „Theranosticians“ talent pool by providing online and observational certified education.

ICPO RESEARCH SUPPORT
Theranostics-related grants to foster young talents innovation and centers autonomy in translational research.

ICPO COMMUNITY & EVENTS
Increase centers' global visibility and reach out to new collaborators and patients.

¹⁻³ "Are European Healthcare Systems Prepared for a Potential Rapid Rise in Radioligand Therapy Eligible Patient Numbers?", Leonhard Schaetz, Margarida Goulart, Roberta Cirillo, Diego Hernandez, Platon Peristeris, Andreas Poschenrieder, Panagiota Papaioannou, Panos Kanavo, Christian la Fougère, Uwe Holzwarth, et al. Poster presented at ESMO Congress 2025, October 2025.




FACTS & FIGURES 2025




The ICPO Foundation office is located in Wiesbaden near Frankfurt on the ground floor of a Wilhelminian-style house.

Operating Budget 2025



Number of ICPO Clinical Theranostics Centers of Excellence



ICPO Academy for Theranostics ...

... Learners

800+




from 30+ countries


ICPO Academy for Theranostics ...

... Pillars

- RPO Radiomolecular Precision Oncology
- MP Medical Physics
- RC Radiochemistry
- N&P Nursing & Patient Relationships



Donation & Fundraising Budget 2025 in T€



Total Funding of Research Grants from 2019 till 2025

1,5 Mio €

Average Grant **60,000 €**

ICPO Events



80 Speakers in total





ICPO THERANOSTICS CENTERS OF EXCELLENCE



ICPO Theranostics Centers of Excellence form the cornerstone of our global effort to increase equitable access to high-quality Theranostics. Through this collaboration, the ICPO Foundation helps Centers worldwide – particularly in low- and middle-income countries – to improve clinical practice, accelerate education, and drive innovation. By joining the ICPO network, Theranostics centers benefit from an accreditation scheme aligned with international standards and shared values from the world’s leading nuclear medicine societies.

ICPO CENTERS ACCREDITATION

#1 Clinical Center of Excellence

- Documentary review
- ICPO Material and visibility

#2 Comprehensive Center of Excellence

Under development

- Live virtual review
- Dedicated support from ICPO experts

#3 Reference Center of Excellence

Under development

- On site audit
- Recommendations towards scaling & translational research

Development and growth

ICPO offers a structured accreditation pathway that recognizes centers’ current achievements and provides a clear roadmap for future development. Whether a center is newly established or already a global leader, this framework ensures adequate support at every stage, enhancing growth and strengthening expertise in theranostics.

Education through the ICPO Academy for Theranostics

One important advantage: ICPO Theranostics Centers gain access to certified education and training provided through the “ICPO Academy for Theranostics” – a multidisciplinary e-learning platform accredited by the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA). ICPO Centers also have the opportunity to host or participate in an observational practical training course developed in collaboration between leading Theranostics experts and ICPO.

Benefits of the ICPO Center Network

The Foundation connects ICPO Centers with international peers and experts, driving valuable collaboration and fostering strategic partnerships to advance clinical practice in individual regions of the world. Centers also benefit from the latest research insights, increased global visibility, patient referrals, and the strengthening of their role within the dedicated international ICPO Theranostics Community. Leaders and staff of ICPO Centers also gain preferred access to ICPO Events featuring world-class programs that accelerate knowledge exchange and clinical practice.




ICPO Clinical Theranostics Centers of Excellence Network

The ICPO Foundation is developing a global network of ICPO Theranostics Centers of Excellence focusing on middle- and low-income countries. Starting with 11 centers in 2024, the network reached more than 50 accredited centers at the end of 2025. ICPO supports its accredited centers to enhance their clinical practice by shared knowledge, international standards and guidelines and also education through the ICPO Academy for Theranostics. Furthermore, ICPO Centers benefit from the exchange with peers, international experts and leaders from the global ICPO Community, with respect to latest research insights, collaboration opportunities aiming at patient referrals and access to innovation, as well as increased global visibility.



Number of ICPO Clinical Centers of Excellence





“Collaborating with the ICPO Foundation, our theranostics center is leading a transformative shift toward precision oncology in South Africa. As an ICPO Theranostics Clinical Center, we benefit from the global community and exchange with world-class experts within the foundation.”

Prof. Mike Sathekge, CEO of Nuclear Medicine Research Infrastructure, Univ. of Pretoria, South Africa



“The best way to move forward is to team up with committed people, with common principles and ideals. At Hospital Angeles Lomas we are honored to have joined in the ICPO Theranostics Clinical Center Network. This alliance will allow us to strengthen educational strategies, improve access to Theranostics and offer better treatment options, with a patient-centered approach.”

Dr. Cecilia Carreras, Head of Nuclear Medicine, Hospital Angeles Lomas, Mexico City, Mexico



“Joining the ICPO Theranostics Centers of Excellence Network marks an important step in our commitment to advancing precision oncology in Jordan. Being part of this international community allows us to share expertise, be at the forefront of the latest developments in Theranostics and collaborate with other leading centers worldwide. With this collaboration we ensure that more patients benefit from cutting-edge, personalized cancer care.”

Prof. Akram Al-Ibraheem, Chairman of the Nuclear Medicine Department at Jordan’s King Hussein Cancer Center, Amman, Jordan and President of AOFNMB

Some ICPO Theranostics Center within the Network



Peking University Cancer Hospital, Beijing, China

Head of Theranostics Center: Prof. Li Ziyu



Dubai Nuclear Medicine & Molecular Imaging Center-Dubai Health, Dubai, UAE

Head of Theranostics Center: Prof. Batool Albalooshi



MISR Radiology Center, Cairo, Egypt

Head of Theranostics Center: Dr. Yehia Omar



St. Luke’s Hospital, Metro Manila, Philippines

Head of Theranostics Center: Dr. Patricia Bautista



TUM University Hospital, Munich, Germany

Head of Theranostics Center: Prof. Matthias Eiber



UMHLANGA Molecular Imaging and Therapy, Umhlanga, South Africa

Head of Theranostics Center: Dr. Masha Maharaj

ICPO ACADEMY FOR THERANOSTICS



The main objective of the ICPO Academy for Theranostics is to disseminate knowledge in Theranostics to improve the outcomes of patients treated with radiopharmaceutical therapies. The curriculum has been developed under the guidance of its President, Prof. Richard P. Baum, pioneer in Theranostics, together with prominent international experts in their respective field. Industry sponsored stipends are available through the ICPO Foundation in various regions of the world to healthcare professionals and scientists.

Comprehensive e-learning platform in evolution

The comprehensive online educational program provides over 30 carefully selected teaching units and features over 50 hours of content available in more than ten languages. The primary audiences of the ICPO Academy for Theranostics

are clinicians, researchers, physicists and radiochemists as well as nurses, technologists and patient care coordinators.

New content featuring the advanced level of the Academy for Theranostics is in preparation with key contribution from Prof. Rodney Hicks, Prof. Désirée Deandreis, Dr. Vasko Kramer and Dr. Ivo Rausch. Clinical cases discussions, multidisciplinary tumor board illustrations and patient care coordination journeys will be part.

Accreditation by UEMS/AMA and endorsements

The ICPO Academy for Theranostics is accredited by the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), with UEMS-EACCME certification ensuring internationally recognized CME credits. To date, eleven regional and national nuclear medicine societies have endorsed the ICPO Academy for Theranostics.

Observational training

In 2025, ICPO piloted its first observational training program for leaders of ICPO Theranostics Centers, marking a significant step in advancing global expertise in Theranostics. This pilot course was co-developed and hosted by Prof. Matthias Eiber at the TUM Theranostics Clinic in Munich, Germany – more centers will follow this pioneering initiative.

ICPO Academy for Theranostics Pillar Leaders



Prof. Richard P. Baum
President of the
ICPO Academy for
Theranostics



Prof. Vikas Prasad

RADIO-
MOLECULAR
PRECISION
ONCOLOGY (RPO)
PILLAR

MEDICAL
PHYSICS (MP)
PILLAR



Prof. Thomas Beyer



Linda Gardner

RADIO-
CHEMISTRY (RC)
PILLAR

NURSING AND
PATIENT
MANAGEMENT
(NP) PILLAR



Prof. Frank Rösch



Josh Mailman



“Through the ICPO Academy for Theranostics, I experienced how structured education and collaborative mentorship can drive innovation in Radiomolecular Precision Oncology, shaping the future of personalized cancer care.”

Dr. Stefani Susilo
RSUP FATMAWATI Hospital,
Jakarta, Indonesia



“The flexibility to learn at my own pace, combined with the detailed content on cutting-edge radio-pharmaceutical development, was incredibly valuable for my growth as a radiochemist.”

Dr. Zamil Dadashov,
Azerbaijan Nuclear Medicine Center,
Baku, Azerbaijan

Accreditations



Endorsements



In cooperation with




IAEA | Atoms for Peace and Development



ICPO Academy for Theranostics



Enhancing Theranostic clinical practice, education for healthcare professionals is key to improved patient treatment outcomes. The ICPO Academy for Theranostics offers a comprehensive curriculum across four pillars: Radiomolecular Precision Oncology, Medical Physics, Radiochemistry, and Nursing & Patient Relationships. Nearly 4,000 hours of teaching have been delivered to over 800 learners worldwide. In 2026, we would like to double this number of learners, thanks to the continued commitment from industry via sponsored stipends allocated primarily in middle- and low-income countries.

Learners Distribution by Region in %



ICPO Academy Pillars

- RPO Radiomolecular Precision Oncology
- MP Medical Physics
- RC Radiochemistry
- N&P Nursing & Patient Relationships



800+
Learners



from **30+** countries



ICPO RESEARCH SUPPORT



Dedicated to driving scientific progress in Theranostics and empowering visionary researchers worldwide, the ICPO Foundation is fueled by generous philanthropic contributions and patient donations. Through ICPO research grants specifically tailored to the dynamic field of Theranostics, the Foundation facilitates groundbreaking advancements in cancer treatment.

ICPO Scientific Advisory Board

Guided by the expertise of our esteemed ICPO Scientific Advisory Board, namely the Chair, Prof. Richard P. Baum, and the Co-Chair, Prof. Frederik L. Giesel, together with 17 leading world experts, ICPO

carefully selects and supports research projects from start to finish. In 2025 we welcomed the new Co-Chair, Prof. Frederik L. Giesel from Duesseldorf, Germany, as well as the new members Prof. Désirée Deandreis from Paris, France, Prof. Patrick Flamen, Brussels, Belgium, Prof. Axel Heidenreich, Cologne, Germany and Prof. Akram Al-Ibraheem from Amman, Jordan.

2025, a new Call for Applications for AI in Theranostics

Identifying unique challenges in a broader clinical adoption of Theranostics, ICPO has structured a new call for applications in June 2025 to address and leverage AI-based enhancements of oncology care applied to Theranostics. 18 applications from 12 different countries across Africa, North America, Asia, and Europe were received and the winning recipient will be announced early in the new year.

Award & Honor presented by ICPO

Furthermore, ICPO recognizes groundbreaking research in Actinium-225 radiopharmaceutical science through the “Maurits W. Geerlings Next Generation Award”. Dr. Nadine Holzleitner, postdoctoral researcher of the Technical University Munich, Germany, received this award during the “ICPO Forum for Theranostics in Precision Oncology” in May 2025 in Munich, Germany. In January 2026, the newly created “Scott Smallwood Honor for Lifetime Achievement in Theranostics” will be handed over for the first time at the Theranostics World Congress in Cape Town, South Africa, honoring outstanding lifetime contribution and dedication to the field of Theranostics. These recognitions underscore ICPO’s commitment to empowering scientific talents and celebrating contributions that truly shape the field of Theranostics.

ICPO Research Support

ICPO is pleased to support and fund academic research in Theranostics, made possible by the generous donations from patients. Through its research grants, ICPO provides vital seed funding for projects led by emerging talents, paving the way for their career growth in Theranostics. Since its founding in 2019, the Foundation has supported Theranostics research with 1,6 million Euros. Furthermore, ICPO has decided to launch dedicated calls for applications, addressing cutting-edge research themes like the AI Call for Application in Theranostics 2025, as well as to develop and present awards and honors for life achievements in Theranostics.

Topics of Research Grants



Research Funding allocated



ICPO Research Grants and Awards

MAURITS W. GEERLINGS NEXT GENERATION AWARD PRESENTED BY ICPO

Since 2023, the Maurits W. Geerlings Next Generation Award nominates young scientists who have contributed to groundbreaking research in the field of actinium-225-related sciences. Dr. Nadine Holzleitner, from TUM, Munich, Germany, received this award during the ICPO Forum for Theranostics in Precision Oncology in May 2025.

Odile Jaume, Karim Bouterfa, Oliver Buck, Nadine Holzleitner, Elcin Zan (f.l.t.r.)



FIRST CALL FOR APPLICATIONS "AI IN THERANOSTICS" LAUNCHED BY ICPO

This new call for applications was launched by ICPO with objective to develop methodologies to curate and standardize Theranostics datasets – imaging & non-imaging – by producing a structured framework and annotation approach. The winner will be announced in 2026 after careful evaluation from among 18 applications from 12 different countries.



SCIENTIFIC ADVISORY BOARD



Chairman
Prof. Richard P. Baum
Curanosticum,
Wiesbaden, Germany



Co-Chair
Prof. Frederik L. Giesel
University Hospital
Duesseldorf, Germany



Prof. Michael Hofman
Peter MacCallum Cancer
Centre,
Melbourne, Australia



Prof. Sze Ting Lee
Olivia Newton-John
Cancer Research Institute,
Melbourne, Australia



Prof. Chen Liu
Peking University Cancer
Hospital,
Peking, China



Prof. Cristina Müller
Paul Scherrer Institute (PSI)
and ETH Zurich,
Switzerland

Guidance by world-class Scientific Advisory Board

The ICPO Foundation is deeply honored that Prof. Richard P. Baum, Chair of the Scientific Advisory Board (SAB), and, since December 2025, Prof. Frederik L. Giesel, Co-Chair of the SAB, are contributing to this committee with their visionary leadership and groundbreaking expertise. Together with 17 renowned international experts from nine different countries, they contribute invaluable scientific and medical guidance in precision oncology and Theranostics to all ICPO activities around the world, including the centers accreditation, the Academy for Theranostics, the evaluation of grants, as well as the creation of education and innovation driven programs.



Prof. Akram Al-Ibraheem
Jordan's King Hussein
Cancer Center,
Amman, Jordan



Prof. Marianne Pavel
University of Erlangen,
Germany



Prof. Martin Pomper
University of Texas
Southwestern Medical
Center, Dallas, USA



Prof. Vikas Prasad
Mallinckrodt Institute of
Radiology, Washington
University in Saint Louis,
USA



Prof. Frank Rösch
Johannes Gutenberg-
University Mainz,
Germany



Prof. Thomas Beyer
Medical University Vienna,
Austria



Prof. Désirée Deandreis
Gustave Roussy Paris, France



Prof. Patrick Flamen,
Institut Jules Bordet,
Brussels, Belgium



Prof. Axel Heidenreich
University of Cologne,
Germany



Prof. Oliver Sartor
Transformational
Prostate Cancer Research
Center – LCMC Health,
Louisiana, USA



Prof. Mike Sathekge
Univ. of Pretoria and Nuclear
Medicine Research Infrastructure,
Pretoria, South Africa



Prof. Andrew Scott
Olivia Newton-John-
Cancer Research Institute,
Melbourne, Australia



Dr. Ralph Wirtz
Stratifyer Molecular
Pathology GmbH,
Cologne, Germany



ICPO COMMUNITY & EVENTS



At the heart of the ICPO Foundation’s mission lies the development of a strong global network of experts dedicated to advancing theranostics. The ICPO Community unites leaders from clinical practice, research, industry, and non-profit associations as well as nuclear medicine societies – all with one vision: to improve patient outcomes with Theranostics globally. Through continuous exchange, shared knowledge, and international collaboration, ICPO fosters a culture of excellence and inclusivity that empowers professionals across all regions of the world.

ICPO Events with world-class programs

The ICPO Foundation hosts two flagship events: First, the ICPO Forum for Theranostics in Precision Oncology, held in person this year with over 40 experts and panelists hosting more than 240 participants at the TUM Campus in Munich, Germany. Second, the ICPO Theranostics Virtual Summit, organized as an online event which will

take place again in Nov 12 & 13, 2026. These conferences connect experts across continents and inspire innovation in Theranostics.



Global cooperations driving impact

Beyond its own events, ICPO actively participates in nuclear medicine and Theranostics congresses worldwide. With the aim of scaling patient access to Theranostics, global collaborations are key to reaching this goal. In 2025, ICPO co-founded the RLT Angels Association together with the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company. Further cooperations were signed with the Brazilian Society of Nuclear Medicine (SBMN) and the Asian Oceania Federation of Nuclear Medicine and Biology (AOFNMB) which now collaborate with the ICPO along with nine other associations in the field.

Initiative regarding international standards & education harmonization

ICPO took the initiative to organize a strategic workshop involving ten world leading organizations in the field of nuclear medicine and medical education. The agenda was to review the common denominators and discrepancies in Theranostics clinical standards and educational requirements, as well as to assess the need for future efforts to harmonize at global scale and thus aim for improved quality of care and cancer patient outcomes.

Feedback from ICPO Summit 2024





ICPO Forum 2025

4th ICPO Forum for Theranostics in Precision Oncology on May 15 & 16, 2025, at the Science Congress Center Munich (Garching) on TUM Campus

Over 40 international experts presented, debated and challenged the latest trends on how to expand patient access to Theranostics. 240 participants enjoyed the stimulating program, ranging from scientific innovation to patient outcomes, and exchanged with colleagues from across the global ICPO Community, with powerful networking opportunities at the industry exhibition and social event.

Next edition: 5th ICPO Forum for Theranostics in Precision Oncology in 2027.

More info: www.icpo.foundation

Video ICPO Forum for Theranostics May 2025



“The ICPO Forum for Theranostics 2025 has demonstrated the fast evolution of our field and current challenges this brings. ICPO has a role to play especially towards low and medium countries which represent huge patient numbers and unmet clinical needs. The interdisciplinary energy created during the ICPO Forum is exactly what we need to advance Theranostics. The discussions clearly illustrated that Theranostics is becoming a new and valuable pillar of precision oncology.”

Prof. Ken Herrmann, Chair of the Department of Nuclear Medicine, University Hospital Essen, Germany

ICPO Summit 2024

2nd ICPO Theranostics Virtual Summit November 15 & 16, 2024

Following the last edition in 2024 with over 400 attendees, the ICPO Summit will reconvene with a trio of chairs: Prof. Richard P. Baum, Prof. Frederik L. Giesel and Prof. Rudolf A. Werner. Look forward to a world-class program strong on multidisciplinary exchanges covering the themes: Rising stars in Theranostics - Beyond PSMA and FAP, Growing space of Alphas – Outlook on untapped potential, and Clinical trials planning – Navigate from hurdles to outcomes.

Next edition: 3rd ICPO Theranostics Virtual Summit November 12 & 13, 2026

More info: www.icpo.foundation

Video ICPO Theranostics Virtual Summit 2024



“I attended every lecture from Boston, USA, and enjoyed every one of them (even today at 3 am in the morning...) including the panels. It was wonderful to see that biological knowledge needs indeed to be fully understood and included in our decision making in order to make the best decision both for the diagnosis and the treatment of cancer on a patient-centric base for clinical trials and in routine care.”

Prof. Annick D. Van den Abbeele, Professor of Radiology, Harvard Medical School, Boston, USA

WHERE YOU MET US

The ICPO Foundation team actively fosters collaboration within the Theranostics community and participates in leading global conferences where the esteemed members of our Scientific Advisory Board as well as distinguished experts from our network moderated inspiring sessions and held cutting-edge talks.

In 2025 we joined for example the ALASBIMN Congress and UroTeragLATAM in Cancun, Mexico; the International Theranostics Summit in Cairo, Egypt; the ISRT in Baku, Azerbaijan and the ICRT in Limassol, Cyprus; the annual meetings of the SNMMI in New Orleans, USA; the CSNM, in Chengdu, China; the EANM in Barcelona, Spain; as well as the AOCNMB in Chennai, India.

During the ICPO Forum for Theranostics in May 2025 and on the occasion of the EANM in Barcelona in October 2025 we hosted ICPO Center Certification Ceremonies and welcomed 36 new ICPO Theranostics Clinical Centers of Excellence from 17 countries around the world.



ICPO Center Certification Ceremony in Barcelona on the occasion of EANM 2025





PATIENT ADVOCACY



Josh: Patient Journey from Diagnosis to International Advocacy

In this interview, Josh and his family gave us insights into his cancer diagnosis, his treatment with radiotheranostics and his new life as an internationally recognized patient advocate.

Josh Mailman's life was forever changed by his diagnosis in 2007. As an athletic man of 46 years showing no signs of illness, the tech entrepreneur went in for his routine annual check-up. His diagnoses: a tumor the size of a softball in his pancreas, with metastases in his liver. Surgery was deemed too risky. At the time, his son was just ten months old. One can imagine the emotional tribute to their young family. Today, however, their son is 19 years old.

Josh's journey as a patient began with attending conferences to learn more about possible treatments. Here he met Prof. Richard P. Baum who treated him with radiotheranostics therapy multiple times over the past years.

Today, Josh is an internationally recognized advocate for patients with neuroendocrine tumors and a strong advocate of nuclear medicine, molecular imaging and integrative oncology. He contributes to many associations and foundations in the US and across the world.



Scott: Importance of Multiple Medical Opinions

In 2014, the hedge fund manager Scott Smallwood was diagnosed with a neuroendocrine tumor in his pancreas, which required a highly complex and life-threatening surgery. The procedure was extremely risky due to the involvement of several major veins with the tumor.

Scott's advice to anyone diagnosed with a neuroendocrine tumor is to seek multiple opinions from various doctors to determine the best treatment plan.

He consulted six different physicians before deciding on surgery. In the years following his surgery, Scott underwent additional treatment including chemotherapy and liver ablation. After

beginning radiopharmaceutical therapy in 2021, Scott experienced remarkable results. By 2023, almost no metastases could be detected. He was also astonished by the lack of significant side effects from the radiotheranostics treatment, apart from some mild fatigue.

However, Scott acknowledges the profound impact of his initial surgery, particularly the challenges caused by the hormonal changes it caused.

He emphasizes the importance of patients being informed by their doctors about the potential for post-surgical depression, which he believes should be treated with appropriate medication.



Tordys: Power of Advanced Imaging in Treatment Choices

In this interview, we spoke with Tordys von Feder, a successful investment manager, living in Germany. Married for 30 years, she has a son and three grandchildren.

In 2017, during a routine check-up, doctors discovered a neuroendocrine tumor in her small intestine. After the tumor was removed at the clinic in Bad Berka, she was advised to undergo a PET/CT scan every six months. Half a year later, additional metastases were detected in her lungs and lymph nodes thanks to advanced radiomolecular diagnostics, part of the radiotheranostics arsenal.

This level of precision and early detection would not have been achieved as

quickly or as easily with conventional methods. In her opinion, detecting cancer sooner is essential for timely and effective treatment.

She is incredibly grateful that her diagnosis was made at such an early stage. During her regular check-ups in the clinic, she exchanged experiences with many other patients. They all shared the feedback that they were relieved to finally find out about radiotheranostics after going through various other treatments.



Gunnar: Benefits of Targeted Therapy on Men's Health

Gunnar Fantoft, a 72-year-old entrepreneur from Aalborg, Denmark. He is married and has three children. Throughout his life, sports have been a vital aspect of his daily routine, and he still actively plays golf, tennis, and soccer.

Despite having no symptoms, Gunnar was advised by his doctor and friends to undergo a prostate-specific antigen (PSA) test. In 2021, the PSA test revealed a very high value, prompting a PET-CT scan that confirmed his diagnosis of prostate cancer. He successfully underwent treatment with theranostics. During his treatment, Gunnar was classified as a super responder to this therapy, experiencing no side effects.


Gunnar emphasizes the critical role of early detection in fighting prostate cancer and chose not to hide his cancer diagnosis and actively shared information with patients and friends.

To describe his therapy, he used a metaphor likening it to search for truffles, explaining that the radiopharmaceuticals would target tumors and metastases in the body, effectively destroying them. This analogy is easy to understand for many people.



KEY GOALS 2026

Expand the ICPO Clinical Theranostics Centers of Excellence Network to over 100 centers and provide international visibility opportunities. Simultaneously, ICPO will pilot support activities to elevate ICPO Centers to higher standards of care, facilitating their advancement and accreditation as Comprehensive Theranostics Centers of Excellence.



Contribute to the RLT Angels Association to pool existing and create new RLT-related resources and make them widely available. Develop and strengthen meaningful and unique partnerships with like-minded organizations and donors that will help us achieve our mission.



Launch advanced e-learning content (level 2 of 3) for the ICPO Academy for Theranostics with UEMS accreditation and in 10+ languages, while matching access for academics with stipends sponsored by partners. The ICPO Academy level 1 is to reach more than 1,000 learners.

Recognize young talents and lifetime scientific achievements in Theranostics by introducing new ICPO Awards & Honors. Ensure promotion of outcomes and funding sustainability for research grants, including the AI in Theranostics series.

Strengthen the global ICPO Community through the organization of the ICPO Theranostics Virtual Summit on November 12 and 13, 2026, ensuring democratic access for all ICPO Centers of Excellence. Advance ICPO communications and community visibility through a new website and increasingly effective social media presence.



DONATE & SUPPORT

Let's shape a new era of cancer care together.



Contact us and support ICPO



As a non-profit, the ICPO Foundation relies on the generosity of corporate and individual donors to continue scaling and democratizing global patient access to Radiomolecular Precision Oncology.

To make a contribution, simply scan the QR code to find the donation option that best suits your location and preferences.

Please note that, depending on your country of residence and the amount donated, you may be eligible for tax benefits.



ICPO ORGANIZATION

ICPO Team



Karim Bouterfa
Academy &
Centers Project
Manager



Dr. Marwa Hakkam
Accreditation &
Centers Project
Director



Odile Jaume
CEO



Martin Reuter
CFO



Juan Davila
Partner Engagement
& Fundraising
Director



Susanne Simon
Head of
Communications
& Community



Andreas Nötzold
Technical Director



Oliver Buck
Trustee



**Prof. Dr.
Richard P. Baum**
Trustee



Sen. h.c. Udo J. Vetter
Chairman



Michael Lee-Chin
Trustee



Katja Schorn
Office Manager



Tadd Wessel
Trustee

ICPO Board of Trustees



THANK YOU LETTER

To ICPO's Community Stakeholders

Setting a higher benchmark for Theranostics is at the core of the ICPO Foundation's mission and can only be achieved collaboratively. We sincerely thank all our stakeholders for their dedication and commitment, which have made our 2025 achievements remarkable.

Our gratitude goes to the ICPO Scientific Advisory Board, chaired by Prof. Richard P. Baum and newly co-chaired by Prof. Frederik L. Giesel, and composed of 17 global scientific experts and Theranostics leaders, for its world-class guidance. Also, special thanks are extended to Prof. Rod Hicks, Australia, Prof. Matthias Eiber, Germany, and Prof. Vikas Prasad, USA, for their time and dedication throughout 2025. Overall, the close collaboration and exchange across ICPO core activities – namely, accreditation of Theranostics Centers, continued Theranostics education, innovation awareness, research support, and the establishment of ICPO events with high-profile international speakers – have been instrumental in building our strong global ICPO Community.

Without the contributions of experts from leading Theranostics centers around the globe, the milestones

in 2025 would not have been achieved. We truly appreciated the interactions during our visits with Prof. Désirée Deandreis, Gustave Roussy in Paris, France, Prof. Wolfgang Weber and Prof. Matthias Eiber, TUM Klinikum Rechts der Isar, Munich, Germany, Prof. Ken Herrmann, University Hospital Essen, Germany, Prof. Felix Mottaghy, University Hospital RWTH Aachen, Germany, Dr. Yehia Omar, MRC Cairo, Egypt, and Dr. Cecilia Carreras, Hospital Angeles Lomas, Mexico City, Mexico, as well as with Dr. Mohamed Zaki, America Hospital Dubai, Prof. Batool Albaloooshi, Dubai Hospital, both UAE, and with Prof. Rudolf A. Werner, LMU Clinic, Munich, Germany.

We are deeply thankful to all collaborating associations & societies in the field of Nuclear Medicine and beyond for their shared vision and support. In particular in the past year, our new collaborations with the Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB), the Brazilian Society of Nuclear Medicine (SBMN), and the Oncidium Foundation – which are further strengthening our efforts to expand global patient access to Theranostics for improved cancer care in their respective regions and across the globe.

Our sincere gratitude also goes to our patients and individual donors for their generosity and personal impact on the ICPO Foundation's mission. It was a great honor to interview the international patient advocate Josh Mailman & his family as well as Scott Smallwood, Tordys von Feder, and Gunnar Fantoft in our office in Wiesbaden. Their personal insights serve as a source of inspiration for all cancer patients worldwide.

Finally, we extend our profound thanks to industry partners for their invaluable support of ICPO's initiatives, including their active participation as sponsors in our "ICPO Forum for Theranostics in Precision Oncology" in May 2025 in Munich. We are looking forward to your continued contribution to the "ICPO Theranostics Virtual Summit" on Nov 12 & 13, 2026.

Let's continue to strengthen collaboration, inspire innovation, and expand patient access!

Your ICPO Foundation Team

TOGETHER WITH ICPO FOR BETTER PATIENT OUTCOMES

ICPO FORUM 2025 SPONSORS



ICPO Foundation
Humboldtstrasse 29
65189 Wiesbaden
Germany
Phone +49 (0) 611-341 486 30
info@icpo.foundation
www.icpo.foundation

